Skip to main content

UCB Renews Agreement for Genedata's Phylosopher and Expressionist Platforms

NEW YORK (GenomeWeb News) —Genedata said today that UCB has renewed and expanded an agreement to use two Genedata software platforms in its lead discovery research.
 
The new agreement will allow UCB to use Genedata's Phylosopher and Expressionist software in its biologics and lead-finding studies for central nervous system disorders and autoimmune and inflammatory disorders that are conducted in the UK and Belgium.
 
The Expressionist biomarker research software includes public and private data and sample information, and its functions have been expanded to include data from UCB’s molecular profiling technology portfolio. The Phylosopher database integrates links between genome sequences and transcriptomics, proteomic and metabolic data, and other information and annotations, as well as disease-relevant phenotype information.
 
Financial terms of the agreement were not released.

Filed under

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.